# ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

> **NCT00404924** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 1140 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** ZD6474 (vandetanib)
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT00404924
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-10
- **Final completion:** 2014-11
- **Target enrollment:** 1140 (ACTUAL)
- **Last updated:** 2016-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404924, "ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00404924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*